Everest Organics has reported a significant turnaround in its financial performance for the quarter ended September 30, 2025, alongside announcing key changes to its board composition. The company, which operates in the Active Pharmaceutical Ingredients (API) and intermediates segment, has shown resilience in the face of operational challenges.

Financial Performance

For the quarter ended September 30, 2025, Everest Organics reported:

The company's performance for the half-year period ending September 30, 2025, also showed improvement:

Board Restructuring

The Board of Directors has approved several changes in its composition:

1. Appointment of Venkata Satya Subbarao Pachigolla as Additional Director (Whole-time Director), subject to shareholder approval via postal ballot.
2. Change in designation of Kirankumar Rampally from Non-Executive Non-Independent to Independent Director.
3. Change in designation of Prasad Venkata Satya Sundara Srikakolapu from Independent Director to Non-Executive Non-Independent.

These changes are aimed at strengthening the company's leadership and governance structure.

Operational Challenges

While the financial results show improvement, the company faces some operational challenges:

1. The company is operating at enhanced production levels without necessary approvals from the Telangana State Pollution Control Board (TSPCB). This could potentially impact the company's going concern status.
2. The auditor's report highlighted that the company has not provided for Rs 143 lakhs in interest claimed by suppliers for delayed payments.

Management's Response

The management has stated that they are addressing the issue with TSPCB and have applied for Consent for Establishment for the enhancement in capacities. The application is pending approval, although the company has obtained an Environmental Clearance Certificate for additional capacities.

Regarding the supplier payments, the management is negotiating with suppliers and expects that the liability for the claimed interest will not subsist.

Conclusion

Despite the operational challenges, Everest Organics has shown a marked improvement in its financial performance. The board restructuring may bring fresh perspectives to address these challenges. However, investors should closely monitor the resolution of regulatory compliance issues and supplier negotiations in the coming quarters.

The company's ability to maintain its improved financial performance while resolving these operational issues will be crucial for its long-term sustainability and growth in the competitive API market.

Everest Organics Limited , a prominent player in the pharmaceutical industry, has announced significant changes in its leadership structure. The company's Board of Directors has approved several key appointments, signaling a continuation of its current management strategy.

Leadership Continuity

The Board has given its nod for the re-appointment of Dr. Srikakarlapudi Sirisha as the Managing Director for a three-year term, commencing from August 10, 2025, to August 09, 2028. Dr. Sirisha, aged 48, holds M.B.B.S and MD degrees and has been associated with the company since 2014. She currently serves as the Chief Executive Officer and brings extensive leadership experience in various aspects of the pharmaceutical industry, including marketing, regulatory excellence, ethical governance, and Research and Development.

In a parallel move, Mr. Srikakarlapudi Harikrishna has been re-appointed as the Whole-time Director for a three-year term, from September 25, 2025, to September 24, 2028. Mr. Harikrishna, aged 46, is a mechanical engineer who joined the company in 2007. His expertise lies in new project planning and commissioning, purchase of engineering products, and regular engineering detailing of the plant.

Both these re-appointments are subject to shareholder approval at the upcoming 32nd Annual General Meeting.

New Company Secretary

The Board has also appointed Ms. Shweta Singh as the new Company Secretary and Compliance Officer, effective August 05, 2025. Ms. Singh is an associate member of the Institute of Company Secretaries of India and holds a Master's degree in Commerce. She brings over three years of experience in handling compliances under various Corporate Laws for both listed and unlisted companies.

Corporate Governance and Transparency

It's worth noting that both Dr. Sirisha and Mr. Harikrishna are promoter directors and are related to each other. This information is disclosed as part of the company's commitment to transparency and good corporate governance practices.

Financial Performance

In addition to these appointments, Everest Organics Limited has reported its unaudited financial results for the quarter ended June 30, 2025. The company has shown a significant turnaround in its performance compared to the same quarter last year.

The company has managed to increase its revenue from operations by 65.84% year-over-year, from ₹3,244.89 lakhs in Q1 FY2025 to ₹5,381.32 lakhs in Q1 FY2026. More importantly, Everest Organics has turned a loss of ₹608.96 lakhs in Q1 FY2025 into a profit of ₹140.52 lakhs in Q1 FY2026, showcasing a remarkable improvement in its financial performance.

These leadership re-appointments and the strong financial turnaround indicate Everest Organics' commitment to maintaining stability in its management while driving growth and profitability. The company appears to be positioning itself for continued success in the pharmaceutical sector.